Blueprint Medicines Corp [BPMC] stock prices are up 5.87% to $110.05 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BPMC shares have gain 25.87% over the last week, with a monthly amount glided 15.37%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Blueprint Medicines Corp [NASDAQ: BPMC] stock has seen the most recent analyst activity on November 14, 2024, when JP Morgan initiated its Overweight rating and assigned the stock a price target of $126. Previously, UBS started tracking the stock with Neutral rating on October 24, 2024, and set its price target to $88. On May 14, 2024, Stephens initiated with a Overweight rating and assigned a price target of $140 on the stock. Leerink Partners upgraded its rating to a Market Perform and increased its price target to $97 on May 06, 2024. Oppenheimer upgraded its rating to a Outperform but $85 remained the price target by the analyst firm on October 27, 2023. Needham reiterated a Buy rating for this stock on August 21, 2023, and upped its price target to $66. In a note dated July 31, 2023, Wells Fargo upgraded an Overweight rating on this stock and boosted its target price from $55 to $82.
The stock price of Blueprint Medicines Corp [BPMC] has been fluctuating between $72.24 and $121.90 over the past year. Currently, Wall Street analysts expect the stock to reach $122.6 within the next 12 months. Blueprint Medicines Corp [NASDAQ: BPMC] shares were valued at $110.05 at the most recent close of the market. An investor can expect a potential return of 11.4% based on the average BPMC price forecast.
Analyzing the BPMC fundamentals
The Blueprint Medicines Corp [NASDAQ:BPMC] reported sales of 434.41M for trailing twelve months, representing a surge of 126.61%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -0.64%, Pretax Profit Margin comes in at -0.29%, and Net Profit Margin reading is -0.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.48 and Total Capital is -0.29. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.51.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 106.43 points at the first support level, and at 102.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 111.97, and for the 2nd resistance point, it is at 113.90.
Ratios To Look Out For
It’s worth pointing out that Blueprint Medicines Corp [NASDAQ:BPMC]’s Current Ratio is 3.32. Also, the Quick Ratio is 3.27, while the Cash Ratio stands at 0.35. Considering the valuation of this stock, the price to sales ratio is 16.09, the price to book ratio is 22.30.
Transactions by insiders
Recent insider trading involved CHRISTOPHER MURRAY, Officer, that happened on Jan 17 ’25 when 2500.0 shares were purchased. Director, Albers Jeffrey W. completed a deal on Jan 13 ’25 to sell 5000.0 shares. Meanwhile, PRINCIPAL ACCOUNTING OFFICER Hurley Ariel sold 2250.0 shares on Jan 13 ’25.
